GlassScriptPhysician profile
Apurva A Modi
NPI 1558300137
$1,139,455.10
in general payments reported to CMS, 2019-2025
29 companies · $228K in 2025
The $228K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210K · 2020: $103K · 2021: $92K · 2022: $129K · 2023: $156K · 2024: $221K · 2025: $228K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $402K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $111K · Travel and Lodging: $66K · Consulting Fee: $14K · Food and Beverage: $11K · Honoraria: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $402,004.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $111,045.00 |
| Travel and Lodging | $66,040.74 |
| Consulting Fee | $13,958.75 |
| Food and Beverage | $10,919.38 |
| Honoraria | $880.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334,964.26 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $306,062.01 | 2019-2025 | Epclusa, Livdelzi, Vemlidy |
| Abbvie INC. | $280,684.44 | 2019-2025 | |
| Madrigal Pharmaceuticals | $97,961.18 | 2024-2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $81,320.74 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $21,400.79 | 2024-2025 | Iqirvo |
| Shionogi INC | $14,180.57 | 2019-2020 | |
| Novo Nordisk INC | $2,667.43 | 2022-2025 | Wegovy |
| Laborie Medical Technologies Corp. | $54.87 | 2024 | Renovarp |
| Eisai INC. | $42.10 | 2023-2024 | |
| Intra-Sana Laboratories | $26.37 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Echosens North America, INC. | $18.27 | 2024 | Fibroscan |
| Dynavax Technologies Corporation | $17.20 | 2025 | Heplisav-B |
| Dova Pharmaceuticals | $16.90 | 2020 | |
| Perspectum Diagnostics LTD | $16.89 | 2023 | Livermultiscan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $14.39 | 2024 | Livmarli |
| Merck Sharp & Dohme LLC | $6.69 | 2020 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apurva Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.